Success Metrics

Clinical Success Rate
85.4%

Based on 35 completed trials

Completion Rate
85%(35/41)
Active Trials
0(0%)
Results Posted
103%(36 trials)
Terminated
6(14%)

Phase Distribution

Ph phase_4
8
18%
Ph not_applicable
5
11%
Ph phase_3
11
25%
Ph phase_2
14
32%
Ph phase_1
6
14%

Phase Distribution

6

Early Stage

14

Mid Stage

19

Late Stage

Phase Distribution44 total trials
Phase 1Safety & dosage
6(13.6%)
Phase 2Efficacy & side effects
14(31.8%)
Phase 3Large-scale testing
11(25.0%)
Phase 4Post-market surveillance
8(18.2%)
N/ANon-phased studies
5(11.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.5%

35 of 44 finished

Non-Completion Rate

20.5%

9 ended early

Currently Active

0

trials recruiting

Total Trials

44

all time

Status Distribution
Completed(35)
Terminated(9)

Detailed Status

Completed35
Terminated6
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
44
Active
0
Success Rate
85.4%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (13.6%)
Phase 214 (31.8%)
Phase 311 (25.0%)
Phase 48 (18.2%)
N/A5 (11.4%)

Trials by Status

completed3580%
terminated614%
withdrawn37%

Recent Activity

Clinical Trials (44)

Showing 20 of 44 trialsScroll for more
NCT01330446Phase 1

Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer

Completed
NCT00893789Phase 3

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

Terminated
NCT00983437Phase 3

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

Terminated
NCT01624480Phase 1

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Completed
NCT01032200Phase 2

Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors

Completed
NCT01256905Not Applicable

Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies

Withdrawn
NCT01096680Phase 2

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

Completed
NCT01019187Phase 2

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

Completed
NCT01317550Not Applicable

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

Completed
NCT01896128Phase 2

Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke

Completed
NCT02468856Phase 1

Effect of Armodafinil on Simulated Driving

Completed
NCT01011218Phase 2

Management of Insomnia in Breast Cancer Patients

Completed
NCT01121536Phase 3

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Terminated
NCT01746043Phase 2

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

Completed
NCT02552303Not Applicable

The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia

Completed
NCT02151253Phase 2

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

Completed
NCT01460628Phase 4

Effect of Nuvigil on Fatigue

Completed
NCT01470651Phase 4

Armodafinil for Patients Starting Hepatitis C Virus Treatment

Terminated
NCT01091974Phase 2

Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy

Completed
NCT00766467Phase 2

A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas

Completed

Drug Details

Intervention Type
DRUG
Total Trials
44